Welcome to our dedicated page for VLON news (Ticker: VLON), a resource for investors and traders seeking the latest updates and insights on VLON stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect VLON's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of VLON's position in the market.
Vallon Pharmaceuticals (NASDAQ: VLON) reported its Q2 2021 financial results and provided updates on its development programs. The company is focused on its ADAIR and ADMIR programs, targeting the substantial ADHD market valued at approximately $9 billion. Vallon aims to complete enrollment in the pivotal SEAL Study by year-end 2021, with NDA submission targeted for Q2 2022. As of June 30, 2021, Vallon had $10.5 million in cash, expected to sustain operations into Q3 2022. The net loss for the quarter was $2.3 million.
Vallon Pharmaceuticals Inc. (NASDAQ: VLON) announced the issuance of European Patent EP3576719B1 for ADAIR, its abuse-deterrent formulation of immediate-release dextroamphetamine. This patent strengthens Vallon's intellectual property as they partner with MEDICE to develop ADAIR for the European market, potentially generating milestone and royalty payments. Vallon continues its clinical trials in the US, including the SEAL Study targeting recreational drug abusers. The patent covers ADAIR's formulation until 2038, enhancing the company’s position in the ADHD treatment landscape.
Vallon Pharmaceuticals (NASDAQ: VLON) released its Q1 2021 financial results, reporting a net loss of $2.6 million. The company successfully completed an $18 million IPO and is on track to report pivotal data from its ADAIR program in 2H 2021. Recent advancements include continued enrollment in the SEAL Study, designed to evaluate the abuse-deterrent formulation of dextroamphetamine for ADHD. Cash reserves stand at approximately $13 million, anticipated to fund operations through Q3 2022. Key executive appointments were also made to bolster the leadership team.
Vallon Pharmaceuticals has appointed Leanne Kelly as its new Chief Financial Officer, bringing over 20 years of experience in finance and management. Her previous roles include leadership positions at companies like OptiNose and Iroko Pharmaceuticals.
Kelly's expertise aligns with Vallon's strategic goals following its IPO. She aims to leverage her extensive background to support the company's growth, particularly as it anticipates pivotal data from its lead clinical candidate, ADAIR, later this year.
Vallon Pharmaceuticals Inc. (NASDAQ: VLON) will host a live video webcast featuring David Baker, President and CEO, on May 18, 2021, at 4:15 PM ET. The event is part of the Q2 Virtual Investor Summit, where management will also engage in one-on-one meetings with registered investors. The presentation will be accessible via the Company’s website and archived for 90 days. Vallon focuses on developing innovative treatments for CNS disorders, including its investigational product candidate, ADAIR, for ADHD and narcolepsy.
Vallon Pharmaceuticals (NASDAQ: VLON) announced that CEO David Baker will participate in the Advances in Neuropsychiatry Panel on April 29, 2021, at 10:30 AM ET. The panel is part of the Annual Neuroscience Innovation Forum taking place from April 28-30, 2021. A video of the company's presentation is available on-demand and will remain accessible until May 26, 2021. Vallon's lead product candidate is ADAIR, an abuse-deterrent formulation of amphetamine for treating ADHD and narcolepsy.
Vallon Pharmaceuticals provided an update on its lead program, ADAIR, an abuse-deterrent formulation of immediate-release dextroamphetamine for treating ADHD. The pivotal SEAL study is on track for topline results in H2 2021, supporting a potential NDA filing in Q2 2022. The U.S. ADHD market is valued at approximately $9 billion. Vallon aims to address the serious issue of prescription stimulant abuse, with over 5 million annual cases in the U.S. The company is also developing ADAIR for Europe and the UK in collaboration with MEDICE.
Vallon Pharmaceuticals (NASDAQ: VLON) reported financial results for 2020, citing a net loss of approximately $4.8 million. Highlights include successful IPO raising $18 million, with plans for NDA filing for ADAIR in Q2 2022 targeting the $9 billion ADHD market. The ADAIR program, designed to deter drug abuse, is progressing towards pivotal data expected in late 2021. The company's focus on abuse-deterrent formulations positions it strategically in a market where over 5 million Americans misuse prescription stimulants annually.
Vallon Pharmaceuticals Inc. (NASDAQ: VLON) announced its participation in the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. David Baker, CEO, will present and engage in one-on-one meetings with registered investors. The presentation will be available for on-demand viewing starting March 9, 2021, at 7:00 AM ET and archived for 90 days. Vallon focuses on developing abuse-deterrent medications for CNS disorders, with its lead product candidate, ADAIR, aimed at treating ADHD and narcolepsy.
Vallon Pharmaceuticals Inc. has appointed Marella Thorell to its Board of Directors, effective February 12, 2021, coinciding with the closing of its initial public offering. With over 30 years of experience in finance and operations, Thorell's expertise in M&A and fundraising is expected to bolster Vallon's growth, particularly as it advances its investigational product candidate, ADAIR, aimed at treating CNS disorders. Vallon views Thorell's leadership as a significant asset during this pivotal phase.
